Abstract
Presentation Description :
The exact origin of the serous retinopathy that can develop in patients with metastatic cancer, who are treated with mitogen-activated protein kinase kinase inhibition, is yet unknown. To further optimize treatment for this vulnerable patient group, an overview of several cell layers of importance and other factors that may be involved in this retinopathy will be provided during this talk.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.